Pediatric Persistent Hypoglycemia Risk Factors at Sohag University Hospital
Summary
NIH registered a new observational clinical trial (NCT07533318) at Sohag University Hospital in Egypt studying endocrine, metabolic, and genetic risk factors of pediatric persistent hypoglycemia. The study will enroll 24 pediatric patients experiencing hypoglycemia beyond the first 3 days of life. Clinical investigators conducting pediatric metabolic research should be aware of this registry entry as part of ongoing surveillance of active hypoglycemia studies.
What changed
NIH registered a new observational clinical trial on ClinicalTrials.gov studying risk factors for pediatric persistent hypoglycemia. The study at Sohag University Hospital in Egypt will examine endocrine, metabolic, and genetic factors in neonates and children with hypoglycemia occurring beyond the first 3 days of life. No intervention is planned; the study is purely observational.
Healthcare providers and clinical investigators should note this registry entry as part of the broader landscape of active pediatric hypoglycemia research. The study contributes to understanding controversial hypoglycemia diagnostic thresholds in neonates, including varying plasma glucose values (47-50 mg/dL) used by AAP and PES for term newborns. This observational data may inform future clinical practice guidelines without imposing new compliance obligations.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of Endocrine, Metabolic, and Genetic Risk Factors of Pediatric Persistent Hypoglycemia at Sohag University Hospital
Observational NCT07533318 Kind: OBSERVATIONAL Apr 16, 2026
Abstract
Glucose is the key metabolic substrate for tissue energy production. In the perinatal period, the mother supplies glucose to the fetus, and for most of the gestational period, the normal lower limit of fetal glucose concentration is around 54 mg/dl (3 mmol/L)(1). During the first 24-48 hours of life, as normal neonates transition from intrauterine to extrauterine life, their plasma glucose (PG) concentrations are typically lower than later in life (2). Distinguishing between transitional neonatal glucose regulation in normal newborns and hypoglycemia that persists or occurs for the first time beyond the first 3 days of life is important for prompt diagnosis and effective treatment to avoid serious consequences, including seizures and permanent brain injury (2) The definition of hypoglycemia remains controversial in neonates and children. Some approaches define hypoglycemia on the basis of symptoms, others on the PG value. According to the American Academy of Pediatrics (AAP) and Pediatric Endocrine Society (PES), hypoglycemia is diagnosed when plasma glucose is, respectively, <47 mg/dL and <50 mg/dL in at term newborns during the first 48 h of life. Different threshold values have been proposed for pre-term infants (3,4) .
In at-term newborns after the first 48 h of life, infants and younger children, hypoglycemia is defined when plasma glucose is <50 mg/dL. This threshold value is low enough to avoid false-positive results, but is unlikely to lead to permanent neurolo...
Conditions: Hypoglycaemia
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.